DNA-launched live-attenuated vaccines for biodefense applications

Peter Pushko, Igor S. Lukashevich, Scott Weaver, Irina Tretyakova

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

A novel vaccine platform uses DNA immunization to launch live-attenuated virus vaccines in vivo. This technology has been applied for vaccine development against positive-strand RNA viruses with global public health impact including alphaviruses and flaviviruses. The DNA-launched vaccine represents the recombinant plasmid that encodes the full-length genomic RNA of live-attenuated virus downstream from a eukaryotic promoter. When administered in vivo, the genomic RNA of live-attenuated virus is transcribed. The RNA initiates limited replication of a genetically defined, live-attenuated vaccine virus in the tissues of the vaccine recipient, thereby inducing a protective immune response. This platform combines the strengths of reverse genetics, DNA immunization and the advantages of live-attenuated vaccines, resulting in a reduced chance of genetic reversions, increased safety, and improved immunization. With this vaccine technology, the field of DNA vaccines is expanded from those that express subunit antigens to include a novel type of DNA vaccines that launch live-attenuated viruses.

Original languageEnglish (US)
Pages (from-to)1-12
Number of pages12
JournalExpert Review of Vaccines
DOIs
StateAccepted/In press - Apr 25 2016

Fingerprint

Attenuated Vaccines
DNA Vaccines
Viruses
Vaccines
DNA
Immunization
RNA
Alphavirus
Technology
Reverse Genetics
Flavivirus
RNA Viruses
Plasmids
Public Health
Safety
Antigens

Keywords

  • alphavirus
  • chikungunya
  • DNA vaccine
  • flavivirus
  • live-attenuated vaccine
  • Venezuelan equine encephalitis
  • yellow fever

ASJC Scopus subject areas

  • Immunology
  • Drug Discovery
  • Pharmacology
  • Molecular Medicine

Cite this

DNA-launched live-attenuated vaccines for biodefense applications. / Pushko, Peter; Lukashevich, Igor S.; Weaver, Scott; Tretyakova, Irina.

In: Expert Review of Vaccines, 25.04.2016, p. 1-12.

Research output: Contribution to journalArticle

Pushko, Peter ; Lukashevich, Igor S. ; Weaver, Scott ; Tretyakova, Irina. / DNA-launched live-attenuated vaccines for biodefense applications. In: Expert Review of Vaccines. 2016 ; pp. 1-12.
@article{8ee272c8d95b47cabec49623a782c611,
title = "DNA-launched live-attenuated vaccines for biodefense applications",
abstract = "A novel vaccine platform uses DNA immunization to launch live-attenuated virus vaccines in vivo. This technology has been applied for vaccine development against positive-strand RNA viruses with global public health impact including alphaviruses and flaviviruses. The DNA-launched vaccine represents the recombinant plasmid that encodes the full-length genomic RNA of live-attenuated virus downstream from a eukaryotic promoter. When administered in vivo, the genomic RNA of live-attenuated virus is transcribed. The RNA initiates limited replication of a genetically defined, live-attenuated vaccine virus in the tissues of the vaccine recipient, thereby inducing a protective immune response. This platform combines the strengths of reverse genetics, DNA immunization and the advantages of live-attenuated vaccines, resulting in a reduced chance of genetic reversions, increased safety, and improved immunization. With this vaccine technology, the field of DNA vaccines is expanded from those that express subunit antigens to include a novel type of DNA vaccines that launch live-attenuated viruses.",
keywords = "alphavirus, chikungunya, DNA vaccine, flavivirus, live-attenuated vaccine, Venezuelan equine encephalitis, yellow fever",
author = "Peter Pushko and Lukashevich, {Igor S.} and Scott Weaver and Irina Tretyakova",
year = "2016",
month = "4",
day = "25",
doi = "10.1080/14760584.2016.1175943",
language = "English (US)",
pages = "1--12",
journal = "Expert Review of Vaccines",
issn = "1476-0584",
publisher = "Expert Reviews Ltd.",

}

TY - JOUR

T1 - DNA-launched live-attenuated vaccines for biodefense applications

AU - Pushko, Peter

AU - Lukashevich, Igor S.

AU - Weaver, Scott

AU - Tretyakova, Irina

PY - 2016/4/25

Y1 - 2016/4/25

N2 - A novel vaccine platform uses DNA immunization to launch live-attenuated virus vaccines in vivo. This technology has been applied for vaccine development against positive-strand RNA viruses with global public health impact including alphaviruses and flaviviruses. The DNA-launched vaccine represents the recombinant plasmid that encodes the full-length genomic RNA of live-attenuated virus downstream from a eukaryotic promoter. When administered in vivo, the genomic RNA of live-attenuated virus is transcribed. The RNA initiates limited replication of a genetically defined, live-attenuated vaccine virus in the tissues of the vaccine recipient, thereby inducing a protective immune response. This platform combines the strengths of reverse genetics, DNA immunization and the advantages of live-attenuated vaccines, resulting in a reduced chance of genetic reversions, increased safety, and improved immunization. With this vaccine technology, the field of DNA vaccines is expanded from those that express subunit antigens to include a novel type of DNA vaccines that launch live-attenuated viruses.

AB - A novel vaccine platform uses DNA immunization to launch live-attenuated virus vaccines in vivo. This technology has been applied for vaccine development against positive-strand RNA viruses with global public health impact including alphaviruses and flaviviruses. The DNA-launched vaccine represents the recombinant plasmid that encodes the full-length genomic RNA of live-attenuated virus downstream from a eukaryotic promoter. When administered in vivo, the genomic RNA of live-attenuated virus is transcribed. The RNA initiates limited replication of a genetically defined, live-attenuated vaccine virus in the tissues of the vaccine recipient, thereby inducing a protective immune response. This platform combines the strengths of reverse genetics, DNA immunization and the advantages of live-attenuated vaccines, resulting in a reduced chance of genetic reversions, increased safety, and improved immunization. With this vaccine technology, the field of DNA vaccines is expanded from those that express subunit antigens to include a novel type of DNA vaccines that launch live-attenuated viruses.

KW - alphavirus

KW - chikungunya

KW - DNA vaccine

KW - flavivirus

KW - live-attenuated vaccine

KW - Venezuelan equine encephalitis

KW - yellow fever

UR - http://www.scopus.com/inward/record.url?scp=84964547398&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964547398&partnerID=8YFLogxK

U2 - 10.1080/14760584.2016.1175943

DO - 10.1080/14760584.2016.1175943

M3 - Article

SP - 1

EP - 12

JO - Expert Review of Vaccines

JF - Expert Review of Vaccines

SN - 1476-0584

ER -